Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to ...

An investor is ratcheting up the pressure on Acelyrin to pull out of a planned merger with Alumis, setting out its case for ...

GE HealthCare trimmed its financial forecasts for the remainder of the year in the face of U.S. | GE HealthCare said that ...

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Parkinson’s disease has always been a complex puzzle, for patients and researchers alike, with contributing factors ranging ...

Pink slips have followed the green light at Entrada Therapeutics. | Pink slips have followed the green light at Entrada ...